China Delays U.S. Plans To Open Three FDA Foreign Offices
This article was originally published in PharmAsia News
U.S. plans to open a drug-inspection office in China have hit a snag over diplomatic visas. U.S. FDA plans to establish offices in Beijing, Shanghai and Guangzhou, staffed by 13 employees. The Chinese government has endorsed the idea, but the Ministry of Foreign Affairs has not given its formal approval. The agency wants to set up the offices to give it greater ability to ensure the safety of drug products exported to the United States. Once the China offices are opened, FDA has similar plans for India. (Click here for more - a subscription may be required
You may also be interested in...
Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation.
New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.